Bristol-Myers Squibb Company
IMMUNOMODULATORS
Last updated:
Abstract:
The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
Status:
Application
Type:
Utility
Filling date:
2 Oct 2018
Issue date:
17 Sep 2020